- ISIN
- US2307701092
- CUSIP
- 230770109
- Sector
- Healthcare
- IPO Date
- Aug 11, 2009
Highlights
- Market Cap
- $100.09M
- Enterprise Value
- $99.63M
- EPS (TTM)
- -$0.49
- Total Revenue (TTM)
- $41.94M
- Gross Profit (TTM)
- $34.76M
- EBITDA (TTM)
- -$3.18M
- Year Range
- $1.85 - $8.09
- ROA (TTM)
- -10.40%
- ROE (TTM)
- -34.12%
- Avg. Volume (1M)
- 122K
- Avg. Volume Value (1M)
- $842.80K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CPIX Performance Chart
Cumberland Pharmaceuticals Inc. (CPIX) is up 67.8% since the beginning of the year. At $7 per share, CPIX is trading 17.4% below its 52-week high of $8. Investors who bought $1,000 worth of CPIX shares 5 years ago would now be looking at an investment worth $2,055.
Loading charts...
Compare this symbol against anything
Returns By Period
Cumberland Pharmaceuticals Inc. (CPIX) has returned 67.84% so far this year and 89.77% over the past 12 months. Over the last ten years, CPIX has returned 3.85% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Cumberland Pharmaceuticals Inc.
- 1D
- -0.74%
- 1M
- 4.87%
- 6M
- 78.13%
- YTD
- 67.84%
- 1Y
- 89.77%
- 3Y*
- 66.39%
- 5Y*
- 15.50%
- 10Y*
- 3.85%
- ALL TIME*
- -5.36%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
CPIX Monthly Returns History
Based on dividend-adjusted daily data since Aug 11, 2009, CPIX's average daily return is +0.06%, while the average monthly return is +0.69%. At this rate, an investment would double in approximately 8.4 years.
Historically, 45% of months were positive and 55% were negative. The best month was Feb 2025 with a return of +115.0%, while the worst month was May 2010 at -34.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, CPIX closed higher 45% of trading days. The best single day was Nov 30, 2021 with a return of +128.6%, while the worst single day was Jun 25, 2025 at -22.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.78% | 31.20% | -33.94% | 28.92% | 46.78% | 5.37% | 3.09% | 67.84% | |||||
| 2025 | -4.64% | 115.04% | -12.96% | 14.18% | 2.69% | -32.46% | 2.99% | 1.16% | -10.60% | -4.17% | -24.41% | 76.11% | 67.93% |
| 2024 | 16.09% | 2.40% | -21.13% | -4.76% | -7.50% | 3.38% | -6.54% | -5.59% | -5.19% | -12.50% | 25.00% | 69.29% | 32.28% |
| 2023 | 20.44% | -15.13% | -15.22% | -12.31% | -5.85% | -8.70% | 3.40% | 8.55% | 14.55% | 4.76% | -17.17% | 9.25% | -20.37% |
| 2022 | -28.05% | -6.55% | -10.19% | -16.67% | -11.06% | -0.72% | 9.40% | 3.52% | 2.55% | 2.07% | -7.72% | -0.88% | -51.82% |
| 2021 | 7.46% | 7.26% | -10.88% | -11.88% | 10.49% | -3.56% | 14.24% | -11.38% | -6.94% | 0.37% | 86.99% | -7.16% | 58.31% |
Benchmark Metrics
Cumberland Pharmaceuticals Inc. has an annualized alpha of 10.90%, beta of 0.41, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 11, 2009.
- This stock participated in 9.28% of S&P 500 Index downside but only -13.36% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.41 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.90%
- Beta
- 0.41
- R²
- 0.01
- Upside Capture
- -13.36%
- Downside Capture
- 9.28%
Return for Risk
Risk / Return Rank
CPIX ranks 76 for risk / return — above 76% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Cumberland Pharmaceuticals Inc. (CPIX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CPIX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.35 | ||
| Sortino ratioReturn per unit of downside risk | -0.05 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.25 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 1.79 | 2.00 | -0.21 |
| Martin ratioReturn relative to average drawdown | 3.71 | 8.49 | -4.78 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cumberland Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cumberland Pharmaceuticals Inc. was 93.78%, occurring on Nov 22, 2024. The portfolio has not yet recovered.
The current Cumberland Pharmaceuticals Inc. drawdown is 60.81%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-93.78%Nov 2024 | 15y 3mo | — | 16y 11moAug 2009 - now | — |
-1.00%Aug 2009 | 1d | 2d | 2dAug 2009 - Aug 2009 | Financial crisis2007–2009 |
Drawdown Indicators
| CPIX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.78% | -56.78% | -37.00% |
Max Drawdown (1Y)Largest decline over 1 year | -52.62% | -9.10% | -43.52% |
Max Drawdown (3Y)Largest decline over 3 years | -71.94% | -18.90% | -53.04% |
Max Drawdown (5Y)Largest decline over 5 years | -84.73% | -25.43% | -59.30% |
Max Drawdown (10Y)Largest decline over 10 years | -86.68% | -33.92% | -52.76% |
Current DrawdownCurrent decline from peak | -60.81% | -1.58% | -59.23% |
Average DrawdownAverage peak-to-trough decline | -70.69% | -10.70% | -59.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.34% | 2.14% | +23.20% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cumberland Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cumberland Pharmaceuticals Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CPIX relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CPIX has a P/S ratio of 2.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CPIX in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, CPIX has a P/B value of 4.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CPIX
Add Cumberland Pharmaceuticals Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CPIX